AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8123409
Drug: Thiopentone 4
RxNorm normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopentone 4 mg kg‐1 + Suxamethonium 1 mg kg‐1
Trial: 24836213
Drug: Placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for three months
Trial: 26685030
Drug: Postoperative adipose
RxNorm normalized name: human adipose preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adipose derived mesenchymal stem cell treatment
Trial: 18266604
Drug: HGS004 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HGS004 (40 mg/kg)
Trial: 18266604
Drug: HGS004 (8,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HGS004 (8, 20, and 40 mg/kg)
Trial: 18266604
Drug: HGS004 (0.4-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HGS004 (0.4-40 mg/kg)
Trial: 15541412
Drug: ACIDFORM administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACIDFORM administered 0‐30 min precoitus
Trial: 15541412
Drug: 2% nonoxynol‐9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% nonoxynol‐9 (N‐9) product administered 0‐30 min precoitus
Trial: 1146927
Drug: Control cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control cycles (no treatment)
Trial: 11416735
Drug: Structured Treatment
RxNorm normalized name: Lipid,structured (From Sunflower Oil)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured Treatment Interruptions (STI)
Trial: 9285375
Drug: Intranasal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal placebo (0.9% NaCl) followed by intravenous midazolam (0.05 mg/kg)
Trial: 8417420
Drug: Amoxicillin plus
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin plus clavulanate
Trial: 8087515
Drug: Combined chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined chemotherapy and radiotherapy
Trial: 30156200
Drug: SRP followed
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP followed by Er, Cr: YSGG laser treatment
Trial: 21092500
Drug: Continuous femoral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous femoral nerve blockade (CFNB) with ropivacaine 0.2% (median infusion rate 5 ml/h)
Trial: 21092500
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous analgesia (CIA) with fentanyl 30 µg/kg (2 ml/h)
Trial: 9142006
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (40 mg)
Trial: 1657084
Drug: Captopril (6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (6.25 mg)
Trial: 7704492
Drug: Teicoplanin and
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin and aztreonam (antibiotic prophylaxis)
Trial: 24743455
Drug: Aqua lymphatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqua lymphatic therapy (ALT) combined with home-based exercise (n = 13)
Trial: 21353109
Drug: Prednisone (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (administered orally for 4 weeks before IUI)
Trial: 21353109
Drug: Antibody-negative group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody-negative group
Trial: 16670077
Drug: recombinant erythropoietin
RxNorm normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant erythropoietin (epoietin) + granulocyte-colony stimulating factor (G-CSF)
Trial: 10836911
Drug: Daily subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous ardeparin (100 anti‐Xa IU/kg of body weight)
Trial: 8780079
Drug: Zalcitabine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zalcitabine monotherapy (2.25 mg/day)
Trial: 8780079
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (2.25 mg/day ddC with zidovudine)
Trial: 31182874
Drug: Pregabalin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (1 mg/kg of weight)
Trial: 28132867
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg GS-9256 BID
Trial: 28132867
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg GS-9256 QD
Trial: 28132867
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg GS-9256 BID
Trial: 21543993
Drug: Subconjunctival bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subconjunctival bevacizumab (1.25 mg in 0.05 mL)
Trial: 21543993
Drug: Bevacizumab soaked
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab soaked in sponges (1.25 mg in 0.05 mL)
Trial: 19733018
Drug: Dronabinol (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronabinol (oral ingestion of therapeutic THC)
Trial: 17717037
Drug: Medical management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical management with thrombolytic drugs
Trial: 16379317
Drug: TURN treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TURN treatment
Trial: 16379317
Drug: BCG therapy
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG therapy (6 intravesical instillations of Onko BCG)
Trial: 9609216
Drug: Nadroparin (20,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin (20,500 AXa IU/ml) once daily
Trial: 9609216
Drug: Nadroparin (10,250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin (10,250 AXa IU/ml) twice daily
Trial: 28170396
Drug: Conventional drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drugs
Trial: 2226079
Drug: Direct current
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct current therapy
Trial: 389265
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus Bacille Calmette‐Guérin vaccine (BCG)
Trial: 28917544
Drug: Pioglitazone (15-45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (15-45 mg)
Trial: 28917544
Drug: Sulfonylureas (5-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfonylureas (5-15 mg glibenclamide, 2-6 mg glimepiride, or 30-120 mg gliclazide)
Trial: 25775445
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of 25 U of BoNT‐A to the masseter muscle bilaterally (Group I)
Trial: 21746787
Drug: C+P (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C+P (25 g carbohydrate + 10 g whey protein)
Trial: 21746787
Drug: CHO (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO (25 g carbohydrate)
Trial: 16952635
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg tramadol/650 mg acetaminophen orally plus periprostatic 1% lidocaine
Trial: 15252826
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg/day for the first 4 weeks and 10 mg/day for the following 4 weeks)
Trial: 11236074
Drug: Paroxetine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine and Sertraline
Trial: 8420311
Drug: Transdermally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermally administered 17 beta‐estradiol
Trial: 3736737
Drug: Ibopamine, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine, 200 mg and 600 mg
Trial: 3736737
Drug: Indoramin, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoramin, 50 mg
Trial: 27098150
Drug: Trastuzumab/Lapatinib combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab/Lapatinib combination
Trial: 26238121
Drug: Roxadustat 0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxadustat 0.7 mg/kg BIW
Trial: 26238121
Drug: Roxadustat 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxadustat 1.0 mg/kg BIW
Trial: 26238121
Drug: Roxadustat 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxadustat 1.5 mg/kg BIW
Trial: 26238121
Drug: Roxadustat 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxadustat 2.0 mg/kg BIW
Trial: 26238121
Drug: Roxadustat 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxadustat 2.0 mg/kg TIW
Trial: 21123458
Drug: 1100 mg
RxNorm normalized name: mineral oil 1100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1100 mg choline/d
Trial: 9088581
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg sotalol alone (phase 1)
Trial: 9088581
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg sotalol plus 20 ml of antacid (phase 2)
Trial: 9088581
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg sotalol plus antacid given 2 h after sotalol (phase 3)
Trial: 9088581
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of sotalol and MAH
Trial: 1441789
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg recombinant human SOD (rh-SOD) administered intravenously 10-20 minutes prior to reperfusion
Trial: 23651789
Drug: Topical diacerein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diacerein 1%
Trial: 17947606
Drug: rhGH +
RxNorm normalized name: rhGH
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH + parenteral nutrition (PN)
Trial: 17947606
Drug: parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: parenteral nutrition (PN)
Trial: 3122554
Drug: Milk-based food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk-based food supplement
Trial: 3122554
Drug: Milk-based food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk-based food supplement plus breakfast meal
Trial: 3122554
Drug: Lactose solution
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose solution (control)
Trial: 20196640
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (HT) - estradiol and progestogen
Trial: 19904267
Drug: Gemcitabine (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (900 mg m(‐2) over 30 min), oxaliplatin (65 mg m(‐2)), and 5‐FU (1500 mg m(‐2) over 24 h) on days 1 and 8 of a 21‐day cycle
Trial: 19904267
Drug: Gemcitabine, oxaliplatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine, oxaliplatin, and 5‐FU chemotherapy
Trial: 16761242
Drug: Travoprost 0.004%/timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Travoprost 0.004%/timolol 0.5% ophthalmic solution in the morning
Trial: 16761242
Drug: Travoprost 0.004%/timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Travoprost 0.004%/timolol 0.5% ophthalmic solution in the evening
Trial: 11430537
Drug: Neostigmine 0.4-0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.4-0.8 mg/h over 24 h
Trial: 8122736
Drug: Local anaesthetic
RxNorm normalized name: Local anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anaesthetic solution at body temperature (37 +/- 1 degrees C)
Trial: 8122736
Drug: Local anaesthetic
RxNorm normalized name: Local anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anaesthetic solution at room temperature (22 +/- 1 degrees C)
Trial: 24550219
Drug: Short-term intensive
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term intensive insulin therapy (IIT) consisting of basal insulin detemir and premeal insulin aspart for 4 weeks
Trial: 24550219
Drug: Short-term intensive
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term intensive insulin therapy (IIT)
Trial: 18605232
Drug: Daonil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daonil (10 mg glyburide)
Trial: 18605232
Drug: Gen-Glybe (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gen-Glybe (10 mg glyburide)
Trial: 15360941
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of textbook and CAI (CP)
Trial: 23139359
Drug: 80 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/d atorvastatin
Trial: 9227718
Drug: Pranlukast 337.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pranlukast 337.5 mg twice daily
Trial: 9227718
Drug: Pranlukast 225
RxNorm normalized name: pranlukast
DrugBank: Pranlukast (DB01411)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Pranlukast 225 mg twice daily
Trial: 9227718
Drug: Pranlukast (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pranlukast (both doses)
Trial: 8424425
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg tid
Trial: 8424425
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg qid
Trial: 8424425
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg hs
Trial: 3317345
Drug: Recombinant yeast-derived
RxNorm normalized name: YEAST CELL,LIVE DERIVATIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant yeast-derived hepatitis B vaccine (2.5, 5, 10, or 20 micrograms)
Trial: 3317345
Drug: Recombinant yeast-derived
RxNorm normalized name: YEAST CELL,LIVE DERIVATIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant yeast-derived hepatitis B vaccine (20 micrograms booster)
Trial: 3317346
Drug: Plasma-derived hepatitis
RxNorm normalized name: Haptoglobulin 1/1 (Plasma Derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma-derived hepatitis B vaccine (20 micrograms)
Trial: 28846481
Drug: HA and
RxNorm normalized name: rAAV2/1 Hex alpha and beta
DrugBank: CAM-GM201 (DB17687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA and Liposic EDO Gel (Group 2)
Trial: 28846481
Drug: HA, DQS,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA, DQS, and Liposic EDO Gel (Group 3)
Trial: 25533398
Drug: Inhibitors of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibitors of histone deacetylases (HDACi)
Trial: 22139545
Drug: Oral Fructus
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Fructus bruceae oil (20 mL, 3 times per day for 12 weeks) combined with radiotherapy (60‐65 Gy, 6‐7 weeks)
Trial: 19469786
Drug: PGE₁‐EE (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE₁‐EE (maximum 1000 μg) applied transdermally using an adhesive foil patch
Trial: 19469786
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 μg PGE₁‐EE)
Trial: 22228413
Drug: Pulsed dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed dye laser treatment
Trial: 28095541
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with pulsed dye laser and CO2 ablative fractional resurfacing
Trial: 15478785
Drug: Trager treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trager treatment group
Trial: 11875895
Drug: Treatment in
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in a rehabilitation centre in Tenerife for four weeks
Trial: 11875895
Drug: Treatment in
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in two similar centres in Norway for four weeks
Trial: 8179148
Drug: Crystalloid priming
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crystalloid priming solution
Trial: 8179148
Drug: Colloid priming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloid priming solution
Trial: 3117566
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of triglyceride emulsions (LCT; MCT/LCT)
Trial: 29273467
Drug: Peppermint oil
RxNorm normalized name: Peppermint Oil
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peppermint oil capsules (Colpermin)
Trial: 16965866
Drug: Hypofractionated radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated radiation therapy (55 Gy/20 fractions/4 weeks)
Trial: 16965866
Drug: Conventional radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional radiation therapy (64 Gy/32 fractions/6.5 weeks)
Trial: 14756266
Drug: Daclizumab 1
RxNorm normalized name: daclizumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab 1 mg/kg
Trial: 10777469
Drug: New chemotherapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New chemotherapeutic agents (paclitaxel, docetaxel, vinorelbine, gemcitabine, irinotecan)
Trial: 20697547
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy regimens
Trial: 10777469
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and cisplatin-based combination regimens
Trial: 1313340
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin by continuous intravenous infusion
Trial: 29152672
Drug: Original G-CSFs
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original G-CSFs (lenograstim and pegfilgrastim)
Trial: 23460503
Drug: Fesoterodine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine (4 mg, with potential increase to 8 mg after 4 or 8 weeks)
Trial: 23460503
Drug: Fesoterodine (double-blind
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine (double-blind treatment)
Trial: 23460503
Drug: Placebo (double-blind
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (double-blind treatment)
Trial: 22238574
Drug: TAU+FT (Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU+FT (Treatment as Usual plus Family Therapy)
Trial: 11314873
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg citalopram orally 2 hours before ECT
Trial: 9006785
Drug: Sustained-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release theophylline (500 mg) with standard breakfast
Trial: 9006785
Drug: Sustained-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release theophylline (500 mg) with cholecystokinin (0.3 micrograms/kg)
Trial: 9006785
Drug: Sustained-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release theophylline (500 mg) under fasting conditions
Trial: 1428302
Drug: Isradipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (10 mg single dose)
Trial: 1428302
Drug: Slow-release nicardipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release nicardipine (40 mg twice daily for six months)
Trial: 11390120
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol 1 mg/day
Trial: 11390121
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol 2 mg/day
Trial: 8424908
Drug: Single agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single agent cisplatinum
Trial: 3596167
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg) intravenously before tests
Trial: 3596167
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg q.i.d., p.o.) for 1 month
Trial: 3187
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oxytetracycline a day p.o. for 6 weeks after initial treatment with 1 g oxytetracycline a day p.o. for 1 week
Trial: 3187
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 100 mg oxytetracycline and 1.2 g sodiumbituminosulfonates a day p.o. for 6 weeks after initial treatment with 1 g oxytetracycline a day p.o. for 1 week
Trial: 3187
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oxytetracycline a day p.o. for 6 weeks after treatment with combination therapy
Trial: 29149776
Drug: Nebulized 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized 2.5 mg of salbutamol and 2.5 mL of 3% hypertonic saline solution for three consecutive 20-min periods